Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698009 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00698009: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00698009 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00698009, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2). Secondary: * Quantification of cytokine levels; * Assessment of NK cell immunophenotype and function.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mesna
- DRUG Interleukin-2
- BIOLOGICAL Natural Killer Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698009
The ClinicalTrials.gov registry entry for NCT00698009 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00698009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698009 about?
NCT00698009 is a clinical study titled "Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma". Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2). Secondary: * Quantification of cytokine levels; * Assessment of NK cell immunophenotype and function.
What is the current status of trial NCT00698009?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00698009?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mesna (DRUG), Interleukin-2 (DRUG), Natural Killer Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00698009?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.